Omega Therapeutics announces the election of Richard N. Kender

CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of mRNA medicines Programmable Epigenomics, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of shareholders. Mr. Kender’s industry knowledge and proven expertise in corporate finance and business development spanning both large pharmaceutical and emerging biotechnology companies will be instrumental in supporting the company’s business objectives. Company.

“Richard has had a long and impressive career in the industry and brings deep expertise in multiple facets of the pharmaceutical sector, as well as experience as a director of several public biotechnology companies,” said Chris Schade, Chairman of the Board of Directors of Omega Therapeutics. Directors and Growth Partner at Flagship Pioneering. “Omega will greatly benefit from his strategic insights as the company pursues its ambitious vision of pioneering a new class of programmable epigenomic mRNA medicines.” »

Mahesh Karande, President and CEO of Omega Therapeutics added: “I am delighted to welcome Richard to the team. Richard is an industry veteran whose wealth of experience and knowledge in corporate finance, business development and strategic licensing will be invaluable as we continue to capitalize on the vast potential of the OMEGA platform and advance our portfolio of novel epigenomic controllers.

Mr. Kender added: “The potential for epigenomic controllers to modulate almost all human genes opens enormous opportunities for transformative change across a wide range of diseases. I look forward to working with this accomplished board and management team to help realize the full potential of the OMEGA platform and precision epigenomic control.”

Richard N. Kender is a recognized business leader with a long career in the pharmaceutical industry, including 35 years with Merck & Co., Inc. During his tenure at Merck, he held various positions in drug development. the company, particularly in terms of mergers and acquisitions, licenses and financial management. assessment and analysis, and global competitive intelligence. Most recently, he served as Senior Vice President, Business Development and Corporate Licensing from 2000 until his retirement in 2013. During his career, he was involved in numerous strategic transactions and played a instrumental role in Merck’s acquisition of Schering Plow. Mr. Kender currently serves on the board of directors of Seres Therapeutics, POXEL SA, Longeveron Inc. and Bicycle Therapeutics. He holds a Bachelor of Science in Accounting from Villanova University and a Master of Business Administration from Fairleigh Dickinson University.

About Omega Therapeutics

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a wide range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precise epigenomic control of almost all human genes, including historically non-druggable and difficult-to-treat targets, without altering acid sequences. native nucleic acids. Founded in 2017 by Flagship Pioneering following groundbreaking research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished management team with a history of innovation and operational effectiveness. The Company is committed to revolutionizing genomic medicine and has a portfolio of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine and multigenic diseases, including inflammatory and cardiometabolic conditions.

For more information, visit omegatherapeutics.com or follow us on X and LinkedIn.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to historical facts should be considered forward-looking statements, including, without limitation, statements regarding the potential of our development candidates and Mr. Kender’s anticipated instrumental and invaluable impact on the Company in pursuit of its business objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements. expressed or implied by the forward-looking statements. statements, including, without limitation, the following: the new technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and the subsequent obtaining of regulatory approval, or even no way ; the substantial development and regulatory risks associated with epigenomic controllers due to the novel and unprecedented nature of this new class of drugs; our limited operating history; the occurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; volatility in capital markets and general economic conditions; our investments in research and development efforts that further improve the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, particularly for a new class of drugs such as epigenomic controllers; potential delays and unanticipated costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential or result in material adverse consequences; the difficulties in manufacturing the new technology on which our epigenomic controller candidates are based; our ability to adapt to rapid and significant technological changes; our reliance on third parties to manufacture materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates through clinical development; and our ability to adequately obtain, maintain, enforce and protect our intellectual property rights. These and other important factors discussed under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as well as in our other filings with the SEC, could cause cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Although we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to do so, even if subsequent events cause our views to change.